Switching to riociguat: a potential treatment strategy for the management of CTEPH and PAH

Currently, five classes of drug are approved for the treatment of pulmonary arterial hypertension (PAH): phosphodiesterase 5 inhibitors (PDE5i); endothelin receptor antagonists; prostacyclin analogs; the IP receptor agonist selexipag; and the soluble guanylate cyclase (sGC) stimulator riociguat. For...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Pulm Circ
Glavni autori: Benza, Raymond L., Corris, Paul A., Ghofrani, Hossein-Ardeschir, Kanwar, Manreet, McLaughlin, Vallerie V., Raina, Amresh, Simonneau, Gérald
Format: Artigo
Jezik:Inglês
Izdano: SAGE Publications 2020
Teme:
Review Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7074518/
https://ncbi.nlm.nih.gov/pubmed/30803329
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2045894019837849
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items